ClinicalTrialsFinder
RecruitingNot ApplicableNCT07366944

PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes

PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes in Obese Women

Sponsor

Cairo University

Enrollment

40 participants

Start Date

Dec 5, 2025

Study Type

INTERVENTIONAL

Conditions

ObesityPolycystic Ovary SyndromeDry Eye

Summary

Women with polycystic ovarian syndrome (PCOS) may complain dryness of their eyes especially obese ones. lifestye changes are main treatrment fro both problems

Eligibility

Sex: FEMALEMin Age: 30 YearsMax Age: 40 Years

Inclusion Criteria3

  • PCOS women
  • obese class I
  • bilateral dryness of eye

Exclusion Criteria3

  • liver disoease
  • cardiac disease
  • renal disease

Interventions

BEHAVIORALexercise and limiting diet

twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks. Group I, additionally will perform one hour of treadmill walking thrice weekly for 12 weeks.

BEHAVIORALdiet limitation

twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks.

Locations(1)

Cairo University

Giza, Dokki, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07366944

Related Trials

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

NCT0724708425 locations

Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial

NCT070107571 location

Glucose Profiles in Women With Polycystic Ovary Syndrome

NCT074837231 location

Study of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome.

NCT065512851 location

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

NCT074817471 location